CorMedix (CRMD) Non-Current Deferred Tax Liability (2025)
CorMedix (CRMD) reported Non-Current Deferred Tax Liability of $144.6 million for Q4 2025, little changed sequentially from $144.5 million in Q3 2025.
CorMedix (CRMD) Non-Current Deferred Tax Liability (2025) Analysis & Trends
CorMedix (CRMD) has 1 years of Non-Current Deferred Tax Liability data on file, last reported at $144.6 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $144.6 million; the trailing twelve-month figure through Dec 2025 stood at $144.6 million (changed N/A YoY), and the FY2025 full-year result was $144.6 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was little changed at $144.6 million in Q4 2025, from $144.5 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $144.6 million in Q4 2025 to a low of $144.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | CorMedix | 546.82 Mn | 391.62 Mn | 107.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 144.63 Mn |
| Dec 31, 2025 | 144.63 Mn |
| Sep 30, 2025 | 144.53 Mn |
| Sep 30, 2025 | 144.53 Mn |